Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results

Abstract

Summary Four patients underwent intraoperative photodynamic therapy after surgery with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC-PDT) for diffuse malignant mesothelioma. Preliminary procedures were performed in two patients in order to establish the efficacy of mTHPC-PDT and to optimise its tumoricidal effect. The (Faber, 1988). Improved local control does require additional measures, but the disease responds poorly to radio-and chemotherapy (Lerner et al., 1983). As photodynamic therapy (PDT) has been reported to be effective in human mesothelioma xenografts (Feins et al., 1990), it might allow for an appropriate 'clean-up' of the thoracic cavity after surgery. For clinical purposes, the currently used sensitisers for PDT are haematoporphyrin derivatives (HpD) and dihaematoporphyrin ether (DHE) . However, PDT with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC) was superior to DHE-PDT with respect to antitumour activity and tissue selectivity in rodents without causing significant toxicity (Berenbaum, 1989). mTHPC might therefore be better fitted to large surface PDT as required for diffuse malignant mesothelioma treatment. A pilot study was done to evaluate mTHPC-PDT for diffuse malignant mesothelioma with respect to its antitumour activity and the feasibility of a combined modality approach under clinical conditions. Patients and methodsFour patients underwent mTHPC-PDT for diffuse malignant mesothelioma. Each patient was informed in detail about the experimental nature of the procedure and consent was obtained from each patient and from the local Human Investigations Committee of our institution.The four men were aged 46 (patient 1), 48 (patient 2), 65 (patient 3) and 50 years (patient 4), all having had possible occupation related exposure to asbestos. The main symptoms at admission were dyspnoea due to pleural effusion, chest pain and loss of weight. There was no evidence of disease in the peritoneal and contralateral chest cavity on CT-scans at admission. The right side was involved in patients 1, 2 and 4 and the left in patient 3. Previous biopsies revealed an epithelial (Figure la), a biphasic (Figure 2a), a sarcomatous and a mixed type of mesothelioma in the four patients and was confirmed in every case by immunohistologic examinations.Preliminary PDT To establish the efficacy of mTHPC-PDT and to optimise its tumouricidal effect, preliminary PDT was performed in patients 1 and 2 prior to its definitive application. Modulations of mTHPC dose, light dose and of the time interval between mTHPC application and activation were tested. mTHPC (Scotia Pharmaceuticals Ltd, Guildford, UK) was dissolved in 20% ethanol, 30% polyethylene glycol 400 and 50% H20 and administered over 15 min i.v. through a bacterial filter under sterile conditions within 60 min of preparation. Argon-pumped dye laser light of 650 nm (Coherent Innova 200 and Dye CR 599, GMP SA, Lausanne, Switzerland) was delivered through a sterilised optical fibre on tumour areas of 3 cm diameter. The power at the end of the optical fibre was measured wi...

Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy

“…Besides their effectiveness in PDT treatments, poor selectivity for diseased tissues, high dose, extended retention in the host organism, and low wavelength activation (630 nm) were the main drawbacks (7,14). These drawbacks stimulated the development of new PSs showing fast elimination from the body, fewer side effects, and a higher absorption peak (650-800 nm) (6,7,15).…”

“…Despite the improvements achieved, these molecules present low solubility in physiological solutions (6,7,15). For instance, both phthalocyanines and chlorins are hydrophobic PSs that form aggregates in physiological solutions (16).…”

Nanodrug applications in photodynamic therapy

“…This results in a depth of light penetration of at least 1 cm and high tumor selectivity. Light with a wavelength longer than 850 nm is not used due its weak energy which is not enough to initiate a photochemical reaction [13,14,15].…”

Foscan® uptake and tissue distribution in relation to photodynamic efficacy

“…This leads to differential drug levels in tumour vs normal tissue at 2 -4 days after injection. Early clinical data in mesothelioma patients also demonstrated good selectivity, with drug concentrations in the tumour of 5 -14 times that in surrounding normal tissue (pulmonary artery, bronchus, muscle and skin) at 2 -3 days after drug administration (Ris et al, 1991;Braichotte et al, 1992). A study of PDT for metastatic gynaecological cancer (Wierrani et al, 1997) also demonstrated concentration ratios of 3 -6 for tumour/ fatty tissue (retroperitoneal pelvic wall area) in a series of patients biopsied at 4 days after Foscan.…”